Press Room
9 December 2016
Complimentary copy of report „Blockbuster Biologics 2015: Sales of Recombinant Therapeutic Antibodies & Proteins“
STUTTGART, Germany I December 9, 2016 I As a thank you to the visitors of our website and online readers of press releases posted on PipelineReview.com, La Merie Publishing offers a complimentary copy of the report „Blockbuster Biologics 2015: Sales…
Read more10 August 2016
Beyond anti-CD19 CARTs: the future of CAR T-cells depends on the convergence of technologies
STUTTGART, Germany I August 10, 2016 I Immunotherapy of B-cell malignancies with specifically targeted autologous T-cells most probably will see the first adoptive cell therapy products approved in the year 2017. Novartis, Kite Pharma and Juno Therapeutics are in a…
Read more29 May 2016
Increasing impact of biosimilars on the market of originator therapeutic antibodies
STUTTGART, Germany I May 29, 2016 I 2015 was the last year without significant impact of biosimilars on the world of branded originator therapeutic antibodies in regulated markets. The targets of the first wave of biosimilar antibodies are the three…
Read more13 May 2016
Improved next generation of T-cell redirecting bispecific antibodies enters clinical proof-of-concept phase
STUTTGART, Germany I May 13, 2016 I Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields in cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells…
Read more13 March 2016
Biologics sales in 2015 exceeded the USD 150 bln threshold
STUTTGART, Germany I March 13, 2016 I 2015 was another year of record sales of recombinant therapeutic proteins and antibodies despite the beginning commercialization of biosimilar antibodies and proteins. Global sales of originator antibodies and proteins reached USD 154 bln,…
Read more4 February 2016
RORgamma, a hot target for treatment of Th17 cell-mediated immune diseases, but also for immune therapy of cancer
STUTTGART, Germany I February 4, 2016 I Targeting the proinflammatory cytokine interleukin-17 (IL-17) produced by T helper cells has become a clinically validated strategy of successfully treating psoriasis, psoriatic arthritis and ankylosing spondylitis. The first approved and marketed antibody secukinumab…
Read more2 December 2015
Antibody-drug conjugate technology on the path to productivity providing plenty of opportunities
STUTTGART, Germany I December 2, 2015 I Only a few years ago, before the times of immuno-oncology and chimeric antigen receptor (CAR) T-Cell Therapeutics, antibody-drug conjugates (ADC) were the most exciting investment opportunity in oncology which nobody wanted to miss.…
Read more18 March 2015
Innovation with therapeutic antibodies drives 2014 sales of recombinant biologics
STUTTGART, Germany I March 18, 2015 I This year’s systematic comparison of the US$ sales of recombinant therapeutic antibodies and proteins in the year 2014 based on standardized currency exchange rates as of March 17, 2015 suffered from the strong…
Read more12 March 2015
Engineered T-Cell Receptor and T-Cells: independent, but also complementary tools for immuno-oncology with great prospects
STUTTGART, Germany I March 12, 2015 I The T-Cell Receptor (TCR) has emerged as a means to target peptide antigens derived from intracellular proteins in a major histocompatibility complex (MHC) dependent manner. These peptide antigens are presented on the surface…
Read more29 December 2014
Recombinant coagulation factors: market, products, R&D pipeline and new competition from alternative procoagulants and gene & cell therapy
STUTTGART, Germany I December 29, 2014 I Since approval of the first recombinant coagulation factors for treatment and prophylaxis of hemophilia A and B about two decades ago, the market of recombinant coagulation factors has constantly grown to a size…
Read more16 July 2014
Botulinum Neurotoxins: opportunities for biosimilars and biosuperiors to capture market shares (2)
STUTTGART, Germany I July 16, 2014 I A new business report entitled „Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders“ has been released by La Merie Publishing. The worldwide market for botulinum neurotoxins has grown with…
Read more9 May 2014
Recombinant therapeutic antibodies consolidate as growth driver of biologics sales in 2013
STUTTGART, Germany I May 9, 2014 I La Merie Publishing announced today the release of its annual review of the sales of recombinant therapeutic antibodies and proteins. The compilation entitled „2013 Sales of Recombinant Therapeutic Antibodies & Proteins“ shows that…
Read moreFeatured Reports
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
RElated News